US FDA approved a new drug Tremfya that contains guselkumab for the treatment of plaque psoriasis in adult patients. Tremfya/guselkumab belongs to a group of class known as monoclonal antibodies. Psoriasis is basically autoimmune disease characterized as red scaly appearance of patches on skin. Pathologically, psoriasis is classified into 5 different types
- Erythrodermic psoriasis
- Inverse psoriasis
- Plaque psoriasis
- Guttate psoriasis
- Pustular psoriasis
Genetic predisposition is major cause of psoriasis and symptoms may aggravate with environmental factors like winter season or dry weather condition. Similarly, skin infection, psychological stress, drug side effects and diet poor in essential nutrients play important role in the pathogenesis of psorisis. It is a common belief that psorisis is contagious disease but according scientific approach this is not contagious disease because it is connected with exaggerated response of immune system.
Plaque psoriasis is also known as psoriasis vulgaris. It is most common form of psoriasis and globally about 70%-80% cases of psoriasis are associated with plaque psoriasis. Areas that are highly sensitive to plaque psoriasis are knees, scalp, back and elbows. Initially, it appears as silver white scales
on skin which become inflammed with the passage of time. In advance stage patient feels severe itching, swelling of affected areas, pain and inflammation of skin.
Tremfya/guselkumab is inhibits inflammatory responses produced by immune system that play important in the pathology of plaque psoriasis. Tremfya/guselkumab blocks release of inflammatory mediators like interleukin, chemokines and cytokines. According to FDA recommendations this therapy should be reserved for those patients who are not responding to conventional treatment and they are candidates for photo-therapy.
Tremfya/guselkumab Side effects
According to health authorities following side effects were observed during clinical trials.
- Increase risk of infections like tuberculosis
- Reaction of injection site
Tremfya/guselkumab Uses/Patient Information
US FDA Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. At the moment, there not enough data over its usage in pregnancy. However, human antibodies are known to cross placental barrier.
Tremfya/guselkumab is formulated as pre-filled syringe of 100mg/ml. However, it's dosage frequency is 100mg administered subcutaneously at start of therapy then second dose will be administered after 4 weeks. Now, after second dose all subsequent doses will be administered after every 8 weeks interval.